[1] Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. PMID:15653647
[2] Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. DOI:
10.1097/MNM.0000000000001265[3] Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. DOI:
10.1007/s00259-003-1142-0[4] Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. DOI:
10.1007/s002590050034[5] MELPOMENI FANI Damian W Guillaume P Nicolas. Somatostatin Receptor Antagonists for Imaging and Therapy.[J]. Journal of Nuclear Medicine, 2017, 58 Suppl 2: 61S-66S. DOI:
10.2967/jnumed.116.186783
